Bob Parsons
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Veterans, First Responders, and families supporting psychedelic medicine will be honored at the conference for their mental health challenges and the urgent need for better care and resources.
Itzel Barakat, Justin LaPree
MDMA optimizes brain chemistry for safety, openness, and compassion. AEDP uses relational interventions to enhance MDMA's effects in trauma therapy, fostering trust, intimacy, and healing attachment.
Kari Gleiser
James S. Gordon, MD, psychiatrist and author, shares how Mind-Body Skills Groups have reduced PTSD diagnoses by 80%, discussing their techniques and the potential integration of psychedelic experiences.
James Gordon
VA researchers Dr. Chris Stauffer and Dr. Amy Lehrner share insights on their pioneering studies of psychedelic-assisted therapy for PTSD, depression, and substance use in veterans, highlighting clinical models, set and setting, and peer support involvement.
Amy Lehrner, Christopher “Chris” Stauffer
MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.
Keren Tzarfaty, Michael Mithoefer, Julie Holland
Catherine Oxenberg's daughter India survived a traumatic experience in the NXIVM cult, leading to long-lasting scars. The Catherine Oxenberg Foundation now supports survivors of sexual assault with ketamine-assisted psychotherapy retreats.
Vicky Dulai, Catherine Oxenberg, India Oxenberg
Session features the unlikely journey of psychedelic therapy into the VA and updates on current psychedelic research programs.
Marcus Capone, Amber Capone
Psychedelics show promise in treating pain and addiction. Psychedelic policy reform can inspire bipartisan coalitions and benefit drug policy reform overall.
Ethan Nadelmann
